Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Breast Cancer Female, Mus...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Creatine — Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.

Primary Outcomes

  • Change in strength in breast cancer survivors (baseline and 12 weeks)
  • Change in physical functional capacity in breast cancer survivors (baseline and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-29
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Medical Branch, Galveston
Collaborators: ThriveWell Cancer Foundation
Principal Investigators:
  • Darpan Patel, PhD (PRINCIPAL_INVESTIGATOR) - University of Texas
Contact Information
Study Contact:
Lisa Thibodeaux, RN,BSN
4094741756
lbthibod@utmb.edu
Rebecca Geck, MPH,APRN,CPT
4092660496
raschaef@utmb.edu
Lisa Thibodeaux, RN,BSN
409-474-1756
lbthibod@utmb.edu
The University of Texas Medical Branch, Galveston
Interventions
  • Dietary Supplement: Creatine — Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
Study Locations (1 sites)
The University of Texas Medical Branch, Galveston, Galveston, Texas 77555 United States
Eligibility Criteria
Inclusion criteria (Breast Cancer Group) * Age 18-75 years of age * Diagnosis of breast cancer requiring chemotherapy * Recent (within 6 months) completion of chemotherapy * Willing to attend 3 virtual-based exercise sessions per week * Able to take oral medications * Participant is willing and able to provide consent to participating in the study * Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation. Exclusion criteria (Breast Cancer Group) * Physical indications where performing exercise may be limited and/or contraindicated * Poorly controlled hypertension (blood pressure \> 160/95mmHg) * Current tobacco use (within 6 months) * Anabolic steroids use * Pitting edema greater than 2+ * Currently undergoing chemotherapy treatment for cancer * History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation) * Pregnant or plan to become pregnant during the study * Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), or other appetite stimulants * Serum creatinine \> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation * Currently taking creatine supplements * Lack of availability to a smartphone and/or internet Inclusion Criteria (Healthy Age-matched Control Group) * Age 18-75 years of age * Have never been diagnosed with cancer * Willing to provide consent to participate in this study Exclusion Criteria (Healthy Age-matched Control Group) * Physical indications where performing exercise may be limited and/or contraindicated * Poorly controlled hypertension (blood pressure \> 160/95mmHg) * Current tobacco use (within 6 months) * Anabolic steroids use * Pitting edema greater than 2+ * History of cancer diagnosis * History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation) * Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e. hormonal therapy for IVF) * Recent (within one month) treatment with corticosteroids * Recent (within one month) use of appetite stimulants or appetite suppressants * Serum creatinine \> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation * Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or Neurological disorders * Uncontrolled diabetes (A1c of 6.5% or higher) * Currently taking creatine supplements * Lack of availability to a smartphone and/or internet

Metreleptin in Anorexia Nervosa

NCT06305182
Recruiting
Conditions Anorexia Nervosa
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The treatment of anorexia nervosa often proves to be difficult. There are no drugs that work specifically for the treatment of anorexia nervosa. Experimental administration of metreleptin (synthetically produced leptin) to patients with anorexia nervosa has produced positive results. This study tests the effect of metreleptin in comparison with placebo, which could potentially make treatment easier. The aim of the study is to investigate whether treatment with metreleptin can help to reduce the symptoms of anorexia nervosa and improve mood and weight.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Metreleptin — Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake. Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
  • Drug: Sodium chloride — The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.

Primary Outcomes

  • Clinician-rated depression on the 17 point Hamilton Depression Scale (HAMD-17) in the metreleptin-assisted therapy group compared to placebo-therapy group between Baseline, Post Treatment and 5 weeks Follow Up (Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49))
  • Body weight status in the metreleptin-assisted therapy group compared to placebo-therapy group between Baseline, Post Treatment and 5 weeks Follow Up (Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-05-31
Completion: 2026-12-31
Eligibility
Age: 17 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gabriella Milos
Contact Information
Study Contact:
Gabriella Milos, Prof. Dr. med.
0041 44 255 52 80
Gabriella.Milos@usz.ch
Lisa Guth, MSc Psychology
0041 44 255 97 17
Lisa.Guth@usz.ch
Deborah Felder
+41 44 255 52 51
Deborah.Felder@usz.ch
Eating Disorder Unit, Clinic of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich
Interventions
  • Drug: Metreleptin — Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake. Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
  • Drug: Sodium chloride — The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
Study Locations (1 sites)
Eating Disorder Unit, Clinic of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Canton of Zurich 8091 Switzerland
Eligibility Criteria
Main key inclusion criteria: * Current diagnosis of AN according to fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) confirmed with Structured Clinical Interview for DSM-5 (SCID-5) * BMI \> 13 kg/m2; BMI ≤ 18 kg/m2; body weight ≥ 35 kg * Hospitalisation in the Eating Disorders Unit, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital of Zurich * Ability to understand German language * Age range: 17 - 65 years * Depressive symptoms: HAMD-17 ≥ 8 * Negative urine pregnancy test, non-lactating and double birth control * Informed Consent as documented by signature Main key exclusion criteria: * Illicit drug intake within last month; current alcohol use disorder * Severe psychiatric and/or severe somatic comorbidities; f. e. lifetime diagnosis of schizophrenia, bipolar disorder, inflammatory bowel disorders, diabetes mellitus, autoimmune disorders, pancreatitis, neurological disorders, cancer including lymphoma * Acute suicidality or current serious non-suicidal self-injury
Conditions Breast Neoplasm
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: HydroMARK Plus Clip — Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.

Primary Outcomes

  • Retrieval rate of the HydroMARK Plus clip. (Date of HydroMARK Plus Clip placement to 1 week plus or minus 5 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-05
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: Mammotome
Principal Investigators:
  • Ceren Yalniz, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Quenteeria Mooney
205-996-1082
qmooney@uabmc.edu
Quenteeria Mooney
205-996-1082
qmooney@uabmc.edu
The Kirklin Clinic
Ceren Yalniz, MD
The Kirklin Clinic
Interventions
  • Device: HydroMARK Plus Clip — Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
Study Locations (1 sites)
The Kirklin Clinic, Birmingham, Alabama 35249 United States
Eligibility Criteria
Inclusion Criteria: * Patients with biopsy clips scheduled for surgery with SCOUT localization Exclusion Criteria: * Patients who didn't have surgery, patients younger than 18 years old * Patients older than 90 years old * Inmates * Non-English speakers
Conditions Breast Cancer
Phase Not Applicable
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone therapy and family cancer history and 2) investigate individuals on hormone therapy perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Breast Cancer Screening — Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
  • Other: Survey/Interview — A mixed-methods approach including electronic surveys and one on one interviews.
  • Other: Focus Group — A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.

Primary Outcomes

  • Callback and Biopsy Rates after Breast Cancer Screening (3.5 years)
  • Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Individuals on Hormone Therapy (3.5 years)
  • Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening (3.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-17
Completion: 2028-02
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: true
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Principal Investigators:
  • Chandler S Cortina, MD, MS (PRINCIPAL_INVESTIGATOR) - The Medical College of Wisconsin
Contact Information
Study Contact:
Chandler S Cortina, MD, MS
4149551453
ccortina@mcw.edu
Chandler S Cortina, MD, MS
ccortina@mcw..edu
Medical College of Wisconsin
Interventions
  • Diagnostic Test: Breast Cancer Screening — Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
  • Other: Survey/Interview — A mixed-methods approach including electronic surveys and one on one interviews.
  • Other: Focus Group — A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.
Study Locations (1 sites)
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria for Individuals on Hormone Therapy: 1. Males 40-75 years of age with a history of ≥9 months of estrogen and/or progesterone hormone therapy. 2. Females 40-75 years of age with any history of testosterone hormone therapy, with or without cosmetic mastectomy, but have not undergone complete mastectomy. 3. Persons who have undergone breast cancer screening before can participate. 4. Individuals who meet criteria for above eligibility and are ≥30-39 years of age with a 1st or 2nd degree family member with breast cancer. 5. Ability to speak, read, and write in English. 6. Ability to understand a written informed consent document, and the willingness to sign it. Inclusion Criteria for Breast Radiology Faculty: 1. Board-certified radiologist that specializes in breast imaging and are an actively employed faculty member at Froedtert \& the Medical College of Wisconsin (main campus location). 2. Part of the breast radiology faculty who read both ABUS and MMG of the study participants. 3. Ability to speak, read, and write in English. 4. Ability to understand a written informed consent document, and the willingness to sign it. Inclusion Criteria for Breast Radiology Staff: 1. Must be either a technician, nurse, or clerical staff that works with the breast radiology team at Froedtert \& the Medical College of Wisconsin (main campus location). 2. Ability to understand a written informed consent document, and the willingness to sign it. 3. Ability to speak, read, and write in English. Exclusion Criteria for Individuals on Hormone Therapy 1. Females who have undergone or planned to undergo a complete mastectomy. 2. Females who are post-menopausal on estrogen +/- progesterone hormone therapy since it is a well-established risk for breast cancer). 3. A personal history of breast cancer or a known pathogenic gene mutation that increases the risk of breast cancer development (e.g., BRCA1/2, etc.) given that well-defined surveillance and screening recommendations exist for these persons. Exclusion Criteria for Breast Radiology Faculty 1. Not a board-certified radiologist. 2. Does not specialize in breast imaging. 3. Does not read ABUS and MMG and/or has not read imaging for study participants. Exclusion for Breast Radiology Staff 1\. Does not work with the breast radiology team.
Conditions Obesity, Nonalcoholic Fatty Liver, Diabe...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and magnetic resonance spectroscopy \[MRS\] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Dietary consultation weight loss intervention — Participants will meet with a member of the study team biweekly for about 6 months.

Primary Outcomes

  • Insulin sensitivity assessed as insulin-mediated glucose disposal during a hyperinsulinemic-euglycemic clamp procedure. (up to 6 months after the intervention)
  • 24-hour plasma glucose concentration (up to 6 months after the intervention)
  • Macrophage isolation in adipose tissue biopsy (up to 6 months after the intervention)
  • Macrophage isolation in skeletal muscle tissue (up to 6 months after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bettina Mittendorfer
Collaborators: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Washington University School of Medicine
Principal Investigators:
  • Bettina Mittendorfer (PRINCIPAL_INVESTIGATOR) - University of Missouri-Columbia
Contact Information
Study Contact:
Heather McHatton
(573) 882-7619
heathermchatton@health.missouri.edu
Aman Pritish Aher
amanpritishaher@umsystem.edu
Bettina Mittendorfer
573-882-9377
b.mittendorfer@missouri.edu
University of Missouri School of Medicine
Interventions
  • Other: Dietary consultation weight loss intervention — Participants will meet with a member of the study team biweekly for about 6 months.
Study Locations (1 sites)
University of Missouri School of Medicine, Columbia, Missouri 65212 United States
Eligibility Criteria
Inclusion Criteria : * age: ≥18 but ≤70 years * not pregnant or breastfeeding * weight stable and sedentary before enrollment * no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \[MAO\]-Type 2 Diabetes group) * no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer) * participants must fulfil all of the following group-specific inclusion criteria below: Lean group: * Body mass index (BMI) ≥18.5 but \<25.0 kg/m2 * Intrahepatic triglyceride (IHTG) content \<5% * fasting blood glucose concentration: \<100 mg/dl * blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl * Hemoglobin A1C (HbA1c) \<5.7 % Metabolically normal obesity (MNO) group: * BMI ≥30.0 but \<45.0 kg/m2 * IHTG content \<5% * fasting blood glucose concentration: \<100 mg/dl * blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl * HbA1c \<5.7 % Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group: * BMI ≥30.0 but \<45.0 kg/m2 * IHTG content \>7.5% * fasting blood glucose concentration: ≥100 but \<126 mg/dl * blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \<200 mg/dl * HbA1c: ≥5.7 but \<6.4 % MAO-type 2 diabetes group: * BMI ≥30.0 but \<45.0 kg/m2 * clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \>126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge\>200 mg/dl or HbA1c \>6.4 % without medication if not diagnosed and medically treated for diabetes Exclusion Criteria: \- Individuals that do not meet all inclusion Criterion
Conditions Childhood Depression
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional study is to compare the baseline neural mechanisms and parenting in depressed and non-depressed children and to examine baseline neural mechanisms and parenting as predictors of Family-Focused Treatment for Childhood-Depression (FFT-CD) outcomes. The main questions it aims to answer are: * What are differences between depressed and non-depressed participants on baseline neural and parenting indicators? * Do baseline neural and parenting indicators predict response to FFT-CD? * Does change in parenting and neural functioning mediate change in depression from baseline to follow-up? Participants will: * complete baseline clinical measures * complete neuroimaging tasks via Functional Magnetic Resonance Imaging (fMR) * undergo a 12-session course of FFT-CD * complete follow up evaluations and neuroimaging

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Family-Focused Treatment for Childhood-Depression (FFT-CD) — This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is "to stop downward spirals and to start upward spirals"; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors.

Primary Outcomes

  • Depression Treatment Response (4 months (post-treatment))
  • Children's Self Report of Depressive Symptoms (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-20
Completion: 2027-11
Eligibility
Age: 7 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University Charles River Campus
Collaborators: Massachusetts Institute of Technology
Principal Investigators:
  • Martha C Tompson, PhD (PRINCIPAL_INVESTIGATOR) - Boston University Charles River Campus
Contact Information
Study Contact:
Martha C Tompson, PhD
617-353-9495
mtompson@bu.edu
Martha C Tompson, PhD
617-358-4584
mtompson@bu.edu
Boston University
Natalie Marr, BS
6173539610
nmarr@bu.edu
Boston University
Interventions
  • Behavioral: Family-Focused Treatment for Childhood-Depression (FFT-CD) — This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is "to stop downward spirals and to start upward spirals"; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors.
Study Locations (2 sites)
Boston University, Boston, Massachusetts 02215 United States
Athinoula A. Martinos Imaging Center at Massachusetts Institute of Technology, Charlestown, Massachusetts 02129 United States
Eligibility Criteria
Inclusion Criteria: * Children must: * Have a current DSM-5 diagnosis of MDD, Persistent DD, or DDNOS (based on K-SADS-PL) OR not meet criteria for any DSM-5 mental health diagnosis (based on K-SADS-PL) * Be ages 7-12 * Be living with a parent(s) or guardian willing to participate * Be able and willing to provide informed consent/assent Parent must: * Not be currently pregnant * Be able to read, understand consent forms, and provide consent on their child's behalf * Be the biological parent (or grandparent in parental role) of the participating child \& have lived with the child for more than 75% of the child's life. All participants must: * Not have a disturbance that would interfere with participation such as autism spectrum disorder, psychosis, current substance dependence, current use of psychotropic medication, OCD, or MRI contraindication such as metal inside the body or claustrophobia * Be proficient in English Exclusion Criteria: * Thought or other disturbance in the child that would interfere with the ability to participate in treatment or assessments (e.g., psychotic disorder, autism spectrum disorder, OCD, active substance abuse/dependence, intellectual disability, as assessed on KSADS-PL) * Severe conduct disorders in the child that threaten the home stability (e.g. juvenile justice or children's protective service involvement as assessed on KSADS-PL) due to the potential impact on retention * Youth or primary caregivers do not speak English * Either parent or child has contraindications for neuroimaging (e.g., claustrophobia, metal implants, braces, electronically, magnetically, or mechanically activated devices such as cochlear implants) * The child is on an antidepressant medication, as it may complicate neuroimaging interpretation.

CAPABLE Transplant

NCT06326905
Recruiting
Conditions Quality of Life, Depression, End Stage R...
Phase NA
Enrollment 43
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist, 2) as a surgical prehabilitation intervention targeting the pre-frail/ frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial, and 3) pilot test the feasibility and acceptability for CAPABLE Transplant in symptom and waitlist specific metrics amongst low-income active kidney transplant waitlist candidates.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CAPABLE Transplant- Open Label Pilot — As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
  • Behavioral: CAPABLE Transplant- Randomized Control Trial — As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.

Primary Outcomes

  • Waitlist-status as assessed by data obtained by the National Kidney Registry (0, 16 weeks, 32 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-25
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 43 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Melissa Hladek, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins School of Nursing
Contact Information
Study Contact:
Melissa Hladek, PhD
4106142418
mhladek1@jh.edu
Meagan Clemence, MS
410-705-5808
mcleme26@jh.edu
Meagan Clemence, MS
410-705-5808
mcleme26@jh.edu
Johns Hopkins School of Nursing
Interventions
  • Behavioral: CAPABLE Transplant- Open Label Pilot — As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
  • Behavioral: CAPABLE Transplant- Randomized Control Trial — As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
Study Locations (1 sites)
Johns Hopkins School of Nursing, Baltimore, Maryland 21205 United States
Eligibility Criteria
Inclusion Criteria: * Deceased Donor Waitlist * ≥18 years old * Community dwelling * Current Inactive status or active and had been inactive in the last 18 months for cardiovascular disease, frailty, obesity, social support, mental health, incomplete testing OR Active on the waitlist and low-income Exclusion Criteria: * Living Donor Waitlist * Severe cognitive impairment * Inactivity expected to last \> 3 months (eg cancer treatment) * \>4 hospitalizations in the last 12 months * Current home nursing, physical or occupational therapy
Conditions Mild Allergic Asthma
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this exploratory method-development study is to to establish and evaluate novel non-invasive methods to monitor airway inflammation induced by allergen challenge (both by instillation during bronchoscopy and by inhalation) in patients with mild allergic asthma. The investigator wants to further profile and develop the allergen challenge model by investigating the utility of various non-invasive monitoring methods. The hypothesis of the project is that local inflammatory changes in the lung induced by allergen can be captured by gas-enhanced magnetic resonance imaging (MRI) and analysis of exhaled breath. The validation of cellular outcome measures and non-invasive inflammometry can be used in future clinical trials for proof of concept of novel anti-inflammatory medications. Participants will undergo * methacholine challenge * 2 inhaled allergen challenges * 2 MRI with hyperpolarized xenon and gadolinium based contrast agent * 2 bronchoscopies with bronchoalveolar lavage (BAL) * segmental allergen challenge during the first bronchoscopy * spirometry * skin prick test and skin prick dilution tests * measurement of particles in exhaled air * nasal filter * nasal lavage * sputum induction * peak flow meter tests * exhaled NO (nictric oxide) * blood sampling (in total approx. 190 ml)

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: allergen challenge — Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.

Primary Outcomes

  • Exploratory (1. priority) Changes in soluble mediators [i.e. IL-4, IL-5, IL-8, IL-13, IL-33, TSLP, IL-1, IL-6, INF-alpha, MMP-9, CXCL1, SP-D, albumin] in Bronchoalveolar lavage (BAL) after segmental allergen challenge (24 hours after segmental allergen challenge)
  • Exploratory (1. priority) Changes in soluble mediators [i.e. IL-4, IL-5, IL-8, IL-13, IL-33, TSLP, IL-1, IL-6, NF-alpha, MMP-9, CXCL1, SP-D, albumin] in Sputum after inhalative allergen challenge (24 hours after segmental allergen challenge)
  • Exploratory (1. priority) Changes in non-invasive exhaled particles [i.e.IL-4, IL-5, IL-8, IL-13, IL-33, TSLP, IL-1, IL-6, NF-alpha, MMP-9, CXCL1, SP-D, albumin]after inhalative allergen challenge (before, 3, 6 and 24 hours after inhaled allergen challenge)
  • Exploratory (1. priority) Changes in non-invasive exhaled particles [i.e.IL-4, IL-5, IL-8, IL-13, IL-33, TSLP, IL-1, IL-6, NF-alpha, MMP-9, CXCL1, SP-D, albumin]after segmental allergen challenge (before, 3, 6 and 24 hours after segmental allergen challenge)
  • Exploratory (1. priority) Changes in cell analyzation in BAL [i.e.total cells, neutrophil granulocytes, eosinophil granulocytes, basophil granulocytes, monocytes/macrophages, lymphocytes and dendritic cells] after segmental allergen challenge (24 hours after segemental allergen challenge)
  • Exploratory (1. priority) Changes in cell analyzation in Sputum [i.e.total cells, neutrophil granulocytes, eosinophil granulocytes, basophil granulocytes, monocytes/macrophages, lymphocytes and dendritic cells] after inhalative allergen challenge (before, 6 and 24 hours after inhaled allergen challenge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-09
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
Contact Information
Study Contact:
Jens Hohlfeld, Prof. Dr.
+49 511 5350-8101
jens.hohlfeld@item.fraunhofer.de
Jens M Hohlfeld
jens.hohlfeld@item.fraunhofer.de
Fraunhofer Institute for Toxicology and Experimental Medicine
Interventions
  • Other: allergen challenge — Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
Study Locations (1 sites)
Fraunhofer Institute for Toxicology and Experimental Medicine, Hanover, Lower Saxony 30625 Germany
Eligibility Criteria
Inclusion Criteria: 1. Able and willing to give written informed consent. 2. Male and female subjects aged 18-65 years. Women will be considered for inclusion if they are: * Not pregnant, as confirmed by pregnancy test (see assessment schedule), and not nursing. * Of non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarcheal or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the Screening Visit). * Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence, implants, injectables, combined oral contraceptives, hormonal Intrauterine Devices (IUDs) or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap). 3. History of mild asthma for at least 12 months prior to the Screening Visit that is well controlled with Short Acting Beta-Adrenergic Stimulator (SABA) only. 4. Body mass index between 18 and 32 kg/m2 5. Normal pulmonary function with forced Expiratory Volume in the first second (FEV1) ≥80% of predicted normal and FEV1/Forced Vital Capacity(FVC) ≥70% at Screening Visit. Calculations will be based on Global Lung Function Initiative (GLI) formula. If the participant fails to meet this criterion on the first measurement, spirometry may be repeated twice. 6. Positive skin prick test (wheal diameter reaction ≥3 mm) for the respective challenge aeroallergen (i.e. tree, weed, grass or house dust mite) at or within 12 months prior to the Screening Visit (if performed and documented at Fraunhofer ITEM). 7. Positive early and late asthmatic response upon incremental inhaled allergen challenge at or prior to the Screening Visit (if performed and documented at Fraunhofer ITEM). 8. Production of adequate sputum with ≥1 x 106 total non-squamous cells at or within 12 month prior to the Screening Visit 1 (if not performed and documented at Fraunhofer ITEM). 9. Nonsmokers with a history of less than 1 pack year having been nonsmokers for at least one year. Exclusion Criteria: 1. Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, urinalysis, vital signs, lung function or ECG at Screening Visit, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study. 2. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, metabolic disease (asymptomatic Gilbert's syndrome is allowed), endocrine disease (stable and asymptomatic hypothyroidism with or without hormone replacement therapy (HRT) is allowed), or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis). 3. Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements. 4. Specific Immunotherapy (SIT) within three years prior to the study. 5. Intake of systemic or inhaled steroids within 4 weeks before Screening Visit 1a. 6. Respiratory tract infection (RTI) within 4 weeks before Screening Visit 1a. 7. Mild to moderate asthma exacerbation within 3 months before Screening Visit 1a. 8. Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures. 9. Suspected hypersensitivity to any ingredients of the medication in line with bronchoscopy (bronchodilators, sedatives and local anesthetics). 10. Conditions or factors, which would make the subject unlikely to be able to undergo bronchoscopy or allergen challenge. 11. Conditions or factors, which would make the subject unlikely to undergo MRI (e.g. due to claustrophobia, cardiac pacemaker, hypersensitivity to MR i.v. contrast imaging agents). 12. Participation in another clinical trial with Investigational Medicinal Product (IMP) 30 days or 5 half-lives, whichever is longer, prior to enrollment. 13. Participation in the observation period of a competing study within 30 days prior to Screening. 14. Segmental allergen challenge three months prior to bronchoscopy. 15. Donation of more than 400 ml of blood the preceding 60 days before screening. 16. History of regular drug or alcohol abuse 17. Risk of non-compliance with study procedures. 18. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
Conditions Ovarian Neoplasms, Endometrial Neoplasms...
Phase PHASE1
Enrollment 575
Locations 24 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sofe-M — Intravenous
  • Drug: bevacizumab — IV
  • Drug: carboplatin — IV
  • Drug: Itraconazole — oral
  • Drug: pembrolizumab — IV

Primary Outcomes

  • Phase 1a: To determine the recommended phase 2 dose (RP2D) of Sofe-M (LY4170156) (1 Cycle (21 or 28 days))
  • Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with bevacizumab (1 Cycle (21 or 28 days))
  • Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with carboplatin (1 Cycle (21 or 28 days))
  • Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with pembrolizumab (1 Cycle (21 or 28 days))
  • Phase 1b: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: Overall response rate (ORR) (Up to Approximately 60 Months or 5 Years)
  • Phase 2: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: ORR (Up to Approximately 60 Months or 5 Years)
  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (Up to Approximately 60 Months or 5 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-05-20
Completion: 2029-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 575 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Interventions
  • Drug: Sofe-M — Intravenous
  • Drug: bevacizumab — IV
  • Drug: carboplatin — IV
  • Drug: Itraconazole — oral
  • Drug: pembrolizumab — IV
Study Locations (24 sites)
HonorHealth, Scottsdale, Arizona 85258 United States
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California 92037 United States
Emory University, Atlanta, Georgia 30308 United States
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan 49546 United States
NYU Langone Health - Long Island, Mineola, New York 11501 United States
New York University (NYU) Clinical Cancer Center, New York, New York 10016 United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio 43210 United States
The University of Texas - MD Anderson Cancer Center, Houston, Texas 77030-4000 United States
START Mountain Region, West Valley City, Utah 84119 United States
Eligibility Criteria
Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC) * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer Exclusion Criteria: * Individual with known or suspected uncontrolled central nervous system (CNS) metastases * Individual with history of carcinomatous meningitis * Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * Individual with evidence of corneal keratopathy or history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms) * History of pneumonitis/interstitial lung disease * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Conditions Metastatic Breast Cancer
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tiragolumab — 600mg every 3 weeks (Q3W)
  • Drug: Atezolizumab — 1200mg every 3 weeks (Q3W)
  • Drug: Ipilimumab — 1 mg/kg, maximum of 4 cycles

Primary Outcomes

  • PFS-12 (Assessed at 12 weeks)
  • Incidence of adverse events (Assessed until 90 days after the last dose of study treatment or until initiation of new anti-cancer therapy, whichever occurs first)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-06-12
Completion: 2030-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: Hoffmann-La Roche
Principal Investigators:
  • Marleen Kok, MD (PRINCIPAL_INVESTIGATOR) - Antoni van Leeuwenhoek
Contact Information
Study Contact:
Marleen Kok, MD
+31205129111
m.kok@nki.nl
Manon de Graaf, MD
+31205129111
Marleen Kok, MD
+31205129111
m.kok@nki.nl
Antoni van Leeuwenhoek
Interventions
  • Drug: Tiragolumab — 600mg every 3 weeks (Q3W)
  • Drug: Atezolizumab — 1200mg every 3 weeks (Q3W)
  • Drug: Ipilimumab — 1 mg/kg, maximum of 4 cycles
Study Locations (1 sites)
Antoni van Leeuwenhoek, Amsterdam, North Holland 1066CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Metastatic or incurable locally advanced triple negative breast cancer with confirmation of Estrogen receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2) negativity (ER \<10%, HER2 IHC 0, 1+ or 2+ with no amplification) on a histological biopsy of a metastatic lesion * Patients with PD-L1 negative disease determined using the Combined Positivity Score (CPS\<10) (Dako 22C3 IHC) OR previously treated with anti-PD(L)1 in the (neo)adjuvant or metastatic setting (irrespective of PD-L1 status). * Metastatic lesion accessible for histological biopsy * 18 years or older * World Health Organisation (WHO) performance status of 0 or 1 * Maximum of three lines of chemotherapy, including antibody-drug conjugates and Poly-ADP Ribose Polymerase (PARP)-inhibitors, for metastatic disease and with evidence of progression of disease * Measurable or evaluable disease according to RECIST1.1 * Disease Free Interval (defined as time between first diagnosis or locoregional recurrence and first metastasis) longer than 1 year. This does not apply to patients with de novo metastatic disease or patients who did not receive (neo)adjuvant chemotherapy. * Adequate bone marrow, kidney and liver function Exclusion Criteria: * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris * Symptomatic brain metastases (subjects with asymptomatic brain metastases are eligible if these are free of progression for at least 4 weeks) * History of leptomeningeal disease localization * History of having received other anticancer therapies within 2 weeks of start of the study drug * History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins * Known hypersensitivy to Chinese hamster ovary cell products or to any component of the atezolizumab or tiragolumab formulation * History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression (\>10 mg daily prednisone equivalents) or chronic infections. * Prior treatment with an anti-CTLA4 or anti-TIGIT antibody. * Administration of live vaccine within 30 days of planned start of study therapy. * Active other cancer * Positive test for hepatitis B, hepatitis C, HIV and/or Epstein Barr virus (EBV) * History of uncontrolled serious medical or psychiatric illness * Current pregnancy pregnancy or breastfeeding.
Conditions PDL1 Gene Mutation, Non Small Cell Lung ...
Phase EARLY_PHASE1
Enrollment 30
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD204 in participants with selected solid tumours, to identify the MTDs/ recommended doses of 177Lu-RAD204 for future exploration. The study will consist of a Pre-screening Period (if applicable for PD-L1 testing), a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and dosimetry to 177Lu-RAD204im and a Phase I (Treatment) Period for 177Lu-RAD204tr dose escalation.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: 177Lu-RAD204 — 177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses

Primary Outcomes

  • Time Activity Curves (TACs) (72 hours)
  • Radiation dosimetry of Lu177-RAD204im (72 hours)
  • Pharmacokinetics of 177Lu-RAD204im (72 hours)
  • Biokinetics of 177Lu-RAD204im (72 hours)
  • Safety and tolerability of 177Lu-RAD204tr (6 weeks)
  • Recommended dose(s) of 177Lu-RAD204tr for future exploration (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-06-03
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Radiopharm Theranostics, Ltd
Contact Information
Study Contact:
Dimitris Voliotis, MD
+1 646 535 5017
dv@radiopharmtheranostics.com
Veronica Wong, MD
Veronica.Wong@health.nsw.gov.au
Nepean Hospital
Daniel Brungs, MD
ISLHD-CancerClinicalTrials@health.nsw.gov.au
Wollongong Hospital
Interventions
  • Drug: 177Lu-RAD204 — 177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
Study Locations (5 sites)
Nepean Hospital, Kingswood, New South Wales 2747 Australia
Wollongong Hospital, Wollongong, New South Wales 2500 Australia
Gold Coast University Hospital, Southport, Queensland 4215 Australia
Cancer Research SA (CRSA), Adelaide, South Australia 5000 Australia
GenesisCare Murdoch, Murdoch, Western Australia 6150 Australia
Eligibility Criteria
Inclusion Criteria: 1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures. 2. Adult participants ≥ 18 years of age. 3. Participants with a documented history of histopathologically confirmed relapsed/refractory locally advanced, inoperable or metastatic NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC, endometrial cancer or any cancer that is known to be MMR deficient or MSI high with documented disease progression during or after their most recent line of anticancer therapy. Participants must be refractory to or have refused standard of care therapy (including PD-1/PD-L1 inhibitors) or have refused or have no standard of care therapy available that is likely to provide clinical benefit. 4. Participants with PD-L1 positive NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC, endometrial cancer or any cancer that is known to be MMR deficient or MSI high: * If the participant tumour's PD-L1 expression status is unknown, PD-L1 positivity may be determined in a pre-screening step whereby the participant may be approached to provide written informed consent to have their tumour tissue undergo IHC testing as determined by a validated test (tumour tissue may be obtained from archived samples or from a freshly obtained biopsy). * Any number of prior treatment lines are allowed. 5. Must have at least 1 measurable target lesion according to RECIST version 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 7. Participants must have a life expectancy of ≥ 4 months in the opinion of the Investigator. 8. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Female participants \< 50 years old who meet the criteria for post-menopausal status without previous surgical sterilisation should be considered for further investigation with luteinising hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status. 9. WOCBP must agree to use a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in Section 13.3 of the Protocol. 10. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. All male participants must agree to not donate sperm during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in Section 13.3 of the Protocol. 11. Participants with previously treated brain metastases are eligible to participate if: * they are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality \[magnetic resonance imaging (MRI) or computed tomography (CT) scan\] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-RAD204im, * do not require steroids to treat associated neurological symptoms, and * have no history of leptomeningeal disease or spinal cord compression. * Participants with active brain metastases who have not received brain-directed therapy such as radiotherapy are not eligible to enroll. 12. For Phase I: * Participants must have positive lesion(s) by 177Lu-RAD204im SPECT/CT per central review as described in Image Review Charter, and * Participants without any positive lesion by 177Lu-RAD204im SPECT/CT, e.g. due to poor image quality, may be allowed to enrol on a case-by-case basis at the discretion of the Principal Investigator and in discussion with study Sponsor, provided the participant's tumour is known to express PD-L1. Exclusion Criteria: 1. History of prior organ transplant. 2. Any other known, active malignancy, except for treated cervical intraepithelial neoplasia or non-melanoma skin cancer. Patients with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome. 3. Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time point imaging procedures, etc. 4. Residual toxicity ≥ Grade 2 from prior anti-cancer therapy (except alopecia). 5. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to protein therapeutics, 177Lu-RAD204 or any of its excipients. 6. Inadequate organ functions as reflected in laboratory parameters: * Creatinine clearance or body surface area (BSA) adjusted estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) \< 60 mL/min * Platelet count of \< 80 × 109/L * Absolute neutrophil count (ANC) \< 1.5 × 109/L * Haemoglobin \< 9 g/dL * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × ULN, or \> 5 × ULN for patients with known liver metastases * Total bilirubin \> 1.5 × ULN, except for patients with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 × ULN * For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR \< 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant. 7. Patients requiring blood product transfusion within 4 weeks of first dose of 177Lu-RAD204tr are not eligible to participate. 8. Clinically significant cardiovascular disease including but not limited to: * Unstable angina * Acute myocardial infarction within 6 months prior to screening * New York Heart Association (NYHA) Class II or greater congestive heart failure (see Section 20.6) * Clinically significant abnormalities in rhythm, conduction or morphology on resting ECG (e.g. complete left bundle branch block, third degree heart block) * Uncontrolled hypertension * Known LVEF \< 50% * QT interval corrected for heart rate using Fridericia's formula (QTcF) \> 470 msec for females and QTcF \> 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome. 9. Participation in any other investigational trial at the time of informed consent signature. 10. Pregnant or lactating women. The following exclusion criteria applies to participants in Phase I: 11. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 ha
Conditions Breast Cancer
Phase PHASE2
Enrollment 82
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, single-arm, multicenter Phase II study of patients with advanced HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine therapy。The primary objective of this study was to explore the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with the CDK4/6 inhibitor Dalpiciclib and standard endocrine therapy in advanced HR+/ HER2-breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Adebrelimab — adebrelimab:1200mg intravenously, Q3W.
  • Drug: dalpiciclib — dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.

Primary Outcomes

  • Progression-free survival(PFS) (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-01-11
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 82 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Contact Information
Study Contact:
Xiong huihua
027-83663405
xionghuihua@hotmail.com
Chao tengfei
027-83663409
turnface@126.com
Huihua Xiong, PI
027-83663405
xionghuihua@hotmail.com
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology
Interventions
  • Drug: Adebrelimab — adebrelimab:1200mg intravenously, Q3W.
  • Drug: dalpiciclib — dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
Study Locations (1 sites)
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430000 China
Eligibility Criteria
Inclusion Criteria: 1. Premenopausal/perimenopausal or postmenopausal women aged ≥18 years and ≤75 years; 2. Histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER \>10% tumor cell positive is defined as ER positive, PR \>10% tumor cell positive is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 ++ but negative by FISH test, no amplification, defined as HER2 negative); 3. Locally advanced breast cancer (radical local treatment is not possible) or recurrent metastatic breast cancer; 4. Did not receive any systemic anti-cancer therapy at the stage of recurrence and metastasis or failed to receive first-line endocrine therapy at the advanced stage; 5. Allowed to receive ≤1 line of chemotherapy 6. Have at least one measurable lesion according to RECIST version 1.1 7. Adequate hematology and organ function, including: hemoglobin \> 9 g/dL without blood transfusion or erythropoietin in the past 14 days. ANC ≥ 1.5×109/L without using granulocyte colony stimulating factor in the past 14 days. PLT ≥ 75×109/L without blood transfusion in the past 14 days. TBIL ≤ 1.5 ×ULN (Gilbert syndrome allows ≤ 3 × ULN). ALT and AST ≤ 3 × ULN (if there is liver metastasis, ALT and AST ≤ 5 × ULN). Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula) 8. ECOG score 0 or 1, and life expectancy ≥3 months; 9. Fertile female subjects are required to use a medically approved contraceptive during the study treatment period and for at least 3 months after the last use of the study drug; 10. Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: 1. Previous use of CDK4/6 inhibitors or PD1/PD-L1 monoclonal antibody 2. Uncontrolled central nervous system metastasis (meaning symptoms or the use of glucocorticoids or mannitol to control symptoms); 3. A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia; 4. Radiotherapy, surgery, or other targeted and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks prior to first administration of the study drug; 5. Pregnant or lactating patients; 6. Malignant tumors within the past three years (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ); 7. Significant comorbidities, including mental illnesses that the investigator believes will adversely affect the patient's participation in the study; 8. Those who have received anti-tumor vaccine or have received live vaccine within 4 weeks before the first administration of the investigational drug; 9. Patients with known HBV or HCV infection active phase or HBV DNA≥500, or chronic phase with abnormal liver function; 10. History of active autoimmune disease (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes) 11. A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; History of interstitial lung disease (except radiation pneumonia without hormone therapy) and non-infectious pneumonia; 12. Patients with active infection or who had been treated with systemic immune stimulating factors within 4 weeks prior to enrollment; 13. Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies; 14. Previous thyroid dysfunction; 15. The investigator did not consider the patient suitable for participation in any other conditions of the study